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King Sau
osting by EAbstract A simple chemometrics-assisted spectrophotometric method for the simultaneous determi-
nation of lamivudine and stavudine in pharmaceutical tablets is described. TheUV absorption spectra
of the studied drugs, in the range of 200–310 nm, showed a considerable degree of spectral overlapping
([Di]
0.5 = 94.9%). Resolution of the mixture has been accomplished by using classical least-squares
regression analysis (CLS) and principle components regression analysis methods (PCR). Beer’s law
was obeyed for both drugs in the general concentration ranges of 2–12 and 3–15 lg ml1 for lamivu-
dine and stavudine, respectively. The proposed methods were successfully applied for the determina-
tion of the two drugs in laboratory prepared mixtures. The overall recoveries percent were found
98.58 ± 1.53–101.30 ± 1.35 (CLS) and 98.62 ± 1.65–101.13 ± 1.04 (PCR) for lamivudine and
98.43 ± 1.62–99.42 ± 1.55 (CLS) and 98.23 ± 1.97–101.20 ± 1.79 (PCR) for stavudine, respec-
tively. The commercial tablets percentage content was found 98.10 ± 2.5–102.47 ± 2.94 (CLS) and
99.12 ± 1.71–100.92 ± 1.54 (PCR) for lamivudine and 96.00 ± 2.94–98.17 ± 1.72 (CLS) and
97.40 ± 1.55–97.80 ± 1.92 (PCR) for stavudine, respectively.Goodpercentage recoveries and proper
statistical data obtained with both the laboratory prepared mixtures and the commercial tablets
proved the suitability andefﬁciencyof theproposedprocedures for routine analysis andquality control
purposes with quite satisfactory precision. A comparison of the obtained results from CLS and PCR
were alsoperformedwith thoseobtained fromreportedmethod.TheobtainedF- and t-valuesobtained
indicating no signiﬁcant differences between the results of the proposed and reported methods.
ª 2009 King Saud University. All rights reserved.(A.E.-M.I. Mohamed).
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lsevier1. Introduction
Simultaneous determination of commercial drug mixtures by
using traditional spectrophotometric methods is a difﬁcult
problem in the ﬁeld of analytical chemistry due to considerable
spectral interference. Derivative spectrophotometry and the
H-point standard addition methods have been frequently used
to overcome the problems of interference due to the partial
276 A.E.-M.I. Mohamed, W. Mikrespectral overlapping (Sabry and Khamis, 2000; Tomsu et al.,
2004; Catherine et al., 2004; Palabiyik et al., 2004).
The great advent and wide spread of the laboratory com-
puter has been allowed analytical chemist to use chemometrics
for facile and accurate analysis of drug mixtures. Among these
techniques are the multivariate calibration methods which can
be performed with easily accessible statistical software and
they are currently widely used in pharmaceutical analysis
(Palabiyik et al., 2004; Dinc et al., 2005; Mohamed and Salem,
2005; Salem et al., 2002).
Classical least squares (CLS), partial least-square regression
(PLS) and principal component regression (PCR) are the most
commonly used methods (Palabiyik et al., 2004; Dinc et al.,
2005; Mohamed and Salem, 2005; Salem et al., 2002). On the
other hand, derivative spectrometry is a fast, simple and rapid
technique which is useful for determination of drugs in multi-
component systems as well as in single component formula-
tions in presence of interfering excipients (Tomsu et al.,
2004; Catherine et al., 2004; Palabiyik et al., 2004). It enhances
the qualitative features and thus increases the ﬁngerprinting
utility for selective identiﬁcation and quantiﬁcation of pharma-
ceutical compounds.
HIV/AIDS requires lifelong treatment with potent life sav-
ing drugs that include nucleoside reverse transcriptase inhibi-
tors, non-nucleoside reverse transcriptase inhibitors and
protease inhibitors (Delgado and Reme, 1998; Williams and
Lemke, 2002). Among these lamivudine (20,30-dideoxy-30-thia-
cytidine) and stavudine (20,30-didehydro-3-doexythymidine)
constitute ﬁrst line therapy. Pharmaceutical preparations con-
taining lamivudine together with stavudine are now commonly
found on the market.
Lamivudine (Fig. 1a) is a nucleoside analog having potent
in vitro and in vivo inhibitory activity against HIV reverse
transcriptase. Lamivudine speciﬁcally refers to the (–) enantio-
mer of the cis-racemate and is marketed as tablets in different
strengths. Stavudine (Fig. 1b) is chemically a thymidine nucle-
oside analog. It has a complete and less variable oral absorp-
tion as compared to other nucleoside analogs (Hardman and
Limbird, 2001).
Literature survey reveals several methods that have been
used for quantitative determination of the two drugs individu-
ally, such as UV-spectrophotometry (Indian Pharmacopoeia,
1996a,b; Kapoor et al., 2006; Anbazhagan et al., 2005), HPLC
(Kapoor et al., 2006; Anbazhagan et al., 2005; Sarasa et al.,
2000; Kapoor et al., 2006; Pendela et al., 2009), HPLC with
tandem mass spectrometric detection (Volosov et al., 2002;N
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Figure 1 Structural formulae of lamivudine and stavudine.Hou et al., 2004; Xu et al., 2009; Mistri et al., 2007) and
radio-immunoassay (Kaul et al., 1996).
Very few reports were found that involving simultaneous
determination of the studied drugs in commercial combined
formulations. These methods included derivative spectroscopy
and HPLC (Kapoor et al., 2006) but there is no report involv-
ing the use of multivariate methods.
Lamivudine and stavudine show closely overlapping UV
absorption bands in the range from 200 to 310 nm. Hence, it
is not easily possible to analyze lamivudine and stavudine com-
binations by traditional UV-spectrophotometry. In this study
two chemometric-assisted spectrophotometric methods are
proposed for the simultaneous determination of lamivudine
and stavudine in some laboratory prepared mixtures and in
pharmaceutical preparations present in the Ethiopian market.
Resolution of the mixtures under investigation has been
accomplished mainly by using CLS and PCR methods but
we use also the zero-crossing ﬁrst derivative for the same re-
sults for the comparison proposes although it was previously
reported (Kapoor et al., 2006). The proposed procedures are
simple, rapid, non-expensive and provide a good resolution
of both drugs with the minimal amount of errors and spectral
and background interferences. In addition, the calibration data
for the reference standards can be used for long time without
change, making it a very suitable method for routine analysis
and quality control purposes.2. Experimental
2.1. Apparatus
Spectrophotometric measurements were carried out on a
computerized Spectronic Genesys 2PC, UV/visible Spectro-
photometer (Milton Roy, USA). The absorption spectra of test
and reference solutions were recorded over the range 200–
310 nm. The subsequent statistical manipulation was per-
formed by transferring the spectral data to Microsoft excel
2003 program and processing them with the standard curve
ﬁt package and matrix calculations.
2.2. Chemicals
Pharmaceutical grade lamivudine (Glasko Smith-Kline,
Durham, UK) and stavudine (Hetero Drugs Limited, Hydera-
bad, India) were used as working standards after conﬁrming
their purity and compliance with pharmaceutical requirements.
All other reagents used were analytical grade.
2.3. Pharmaceutical preparation
The following pharmaceutical preparation was purchased
from the local market and subjected to analysis by the pro-
posed procedures; Coviro-LS tablets (Ranbaxy Laboratories
Limited, India) labeled to contain 150 mg lamivudine and
30 mg stavudine for each ﬁlm coated tablet.
2.4. Procedures
2.4.1. Preparation of standards
Into 100-ml volumetric ﬂask an accurately weighed amount
(50 mg) of either of the studies drugs is dissolved in about
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Figure 2 Zero-order spectra for 10 lg of lamivudine (––) and 10
lg/ml of stavudine (- - - - -) indicating the marked overlap between
bands.
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the same solution. The resulting solution is diluted quantita-
tively with 0.1 M hydrochloric acid to obtain the appropriate
dilutions for each drug according to its linear calibration range
or as speciﬁed under the analysis of the laboratory prepared
mixtures.
2.4.2. Sample preparation
Twenty tablets are weighed and ﬁnely powdered. An accu-
rately weighed amount of the powder equivalent to the aver-
aged weight of one tablet is transferred to 100 ml volumetric
ﬂask and diluted to about 80 ml with 0.1 M hydrochloric acid.
The mixture is shacked for about 10 min and then sonicated
for additional 5 min, diluted to 100 ml with 0.1 M hydrochlo-
ric acid and ﬁltered. The ﬁrst portion of ﬁltrate is discarded.
The obtained clear solution is used as stock sample solution.
The stock solution is diluted quantitatively with 0.1 M hydro-
chloric acid to obtain the suitable working sample solutions for
the UV-measurements.
2.4.3. Standard solutions for multivariate calibration
In order to obtain the calibration matrixes for applying CLS
and PCR analysis, 10 solutions of each of the pure components
(lamivudine and stavudine) were prepared with concentrations
ranged from: 2 to 12 and 3 to 15 lg ml1 for lamivudine and
stavudine respectively, as described in Section 2.4.1. These
ranges were previously veriﬁed to obey Beer’s law for each
of the studied drugs in the selected acid solutions. The absorp-
tion data in the range of 200–310 nm (digitized every 1.0 nm)
were subjected to the least squares analysis in order to obtain
the calibration matrix K for each drug (see Section 3). The lab-
oratory prepared mixtures were then prepared by mixing
known amounts of lamivudine with stavudine in different var-
ied proportions as indicated in Table 3, in order to verify the
precision of the method for analysis of such mixtures and
matching the commercial tablets with those having the same
or approximately comparable concentrations.
PCR multivariate analysis follows the same procedure de-
scribed for CLS except that the K matrix must be replaced
by F matrix, which is calculated from the factorized data
instead of absorbance values in case of CLS and A matrix
must be replaced by Aproj. For details of the calculations
see Section 3.
2.4.4. Data processing
Data were processed on an Intel Pentium IV-Veriton 7200D,
PC-compatible computer equipped with the essential statistical
programs for CLS and PCR calculations.
3. Results and discussion
Full spectrum methods usually provide signiﬁcant improve-
ment in precision over methods restricted to a small number
of wavelengths. A convenient method for resolving the mix-
tures, which can in principle be applied to the present case,
is the least square analysis. The simplest of them is the classical
least squares (CLS). It should certainly be preferred when the
selection of variables is simple. In such cases, the regression
coefﬁcients for different selected collinear wavelengths may
have relatively little meaning for interpretation purposes, but
the model performs well, both in the calibration and prediction
stages, provided that the model having linearity between re-sponses and concentrations and the prediction is performed
within the calibration domain. In addition, the baseline effects
and noise are probably non-signiﬁcant or of very low signiﬁ-
cance. Under these conditions CLS is probably the method
to be recommended.
The absorption spectra for the studied drugs in 0.1 M HCl
is shown in Fig. 2. As can be seen, a considerable degree of
spectral overlapping occurs in the region from 200 to
310 nm. The degree of spectral overlapping can be conve-
niently given by (Di)
0.5, where Di is the magnitude of depen-
dency that can be calculated for a two components mixture
from the equation:
Di ¼
P
k2k
t
2
 2
P
k1k
t
1
P
k2k
t
2
where k1 and k2 are the l · n matrices of regression coefﬁcients
for the compounds 1 and 2, respectively.
In case of the presently studied compounds, the spectra
shown in Fig. 2 lead to Di = 0.90 implying a 94.9% of spectral
overlapping for the studied mixtures.
3.1. CLS method
In CLS a linear relationship between absorbance and the com-
ponent concentration at each wavelength is assumed. When
calibration set of m samples of known content with n spectral
variables are measured the relationship is given by the
equation:
A ¼ CKþ E
where A is the m · n matrix of calibration spectra, C the m · l
matrix of component concentrations, K the l · n matrix of
regression coefﬁcient, and E the m · n matrix of spectral errors
residuals not ﬁt by the model. By means of the calibration sam-
ple set, estimation of absorptivities is possible by solving the
matrix K according to the general least-squares solution indi-
cated by the equation:
K ¼ ðCtCÞ1CtA
Analysis is then based on the spectrum (Aun) of the un-
known samples by
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where Cun is the vector of sought for concentrations.
3.2. PCR method
As a ﬁrst step of PCR method, the proper number of compo-
nents in the PCA model must be determined by one of the well
known methods (Henrion and Henrion, 1994). The data from
lamivudine and stavudine mixtures (Fig. 3) indicate that the
residual variance approximately levels off after the second
component and the ﬁrst and second components accounts
for about 99.37% of the total data variance ﬁt by the whole
components.
The main equation for calculating the concentration can be
written as:
C ¼ F:Aproj
where C is the concentration components and F is the regres-
sion matrix of the new coordinates, thus;Figure 3 Screen-plot for principal component model of lamivu-
dine and stavudine mixtures data.
Table 1 Predicted concentrations of pure lamivudine samples in 0.
and PCR calibration methods.
Concentrations (lg ml1) CLS
Found (lg ml1) % ±Relat
2.00 2.06 101.00 ± 1
3.00 3.06 98.67 ± 2.
4.00 3.92 98.00 ± 1.
5.00 4.93 98.80 ± 2.
6.00 5.87 99.17 ± 2.
7.00 6.96 99.43 ± 1.
8.00 8.03 100.40 ± 1
9.00 9.04 100.41 ± 1
10.00 10.00 100.00 ± 1
11.00 10.93 99.40 ± 0.
a Relative errors as calculated from the corresponding calibration modC:Aproj:½Aproj:Atproj1 ¼ F
Then the calculated F-values are used to predict the concen-
trations in an unknown sample from its measured spectrum as
follows:
Cun ¼ F:VtcAun or Cun ¼ Fcal:Aun
where Fcal = the quantity V
t
ct:A pre-calculated at calibration
time.
3.3. Comparison of the results form the proposed methods
Tables 1 and 2 show the actual and predicted amounts ± the
relative errors (%) of the studied drugs as given by the least-
squares regression analysis (CLS) and principle components
regression (PCR) of the spectral data that obtained experimen-
tally in the calibration range of each drug at the wavelength
range from 200 to 310 nm. The results conﬁrm the consider-
able degree of agreement between CLS and PCR techniques
and indicate that these methods are suitable for this analysis
in the given calibration domain for each drug if compared with
results given by the ﬁrst-derivative method especially for
lamivudine.
Several laboratory prepared mixtures of the studied drugs
were subjected to analysis by the two techniques in order to
conﬁrm the suitability of the calibration models for determina-
tion of the studied drugs in the pharmaceutical sample solu-
tions and to verify the precision of the methods for analysis
of such mixtures and matching the commercial dosage forms
with those having comparable concentrations. Table 3 summa-
rizes the results obtained for the suggested binary mixtures. As
can be seen, the concentrations predicted by the models are
considerably close to the real concentrations, the recoveries
in most cases were satisfactory and the deviation range be-
tween the estimated and true concentrations were found be-
tween 0.28% and 1.57% with relative errors between 1.10%
and 2.00% for CLS and 0.03% and 1.77% with relative errors
between 1.04% and 1.97% for PCR, respectively. It can be ob-
served from this set of results that the drug mixtures determi-
nation is feasible for the multivariate procedures (CLS and
PCR), but the factorized multivariate calibration models
(PCR) allows a more signiﬁcant reduction of errors in relation
to the determination by both the CLS procedure, especially in1 M hydrochloric acid ± relative errors as calculated from CLS
PCR
ive errorsa Found (lg ml1) % ±Relative errorsa
.88 1.98 98.80 ± 2.11
21 2.99 99.73 ± 2.23
88 3.99 99.68 ± 1.96
00 5.07 101.40 ± 1.77
37 6.04 100.67 ± 1.98
42 6.95 99.21 ± 1.45
.80 7.98 99.70 ± 2.00
.98 9.08 100.89 ± 1.14
.85 10.13 101.30 ± 1.56
89 10.87 98.82 ± 1.78
el (n= 3).
Table 4 Results from analysis of the studied drugs in Coviro-LS tablets (150 mg lamivudine and 30 mg of stavudine) with the 1D
(reported method), CLS and PCR methods.
Drugs Claimed analyzed
concentrations (lg ml1)
Founda Calculated
t-valuesb
Calculated
F-valuesb1D (% ±SD) CLS (% ±SD) PCR (% ±SD)
Lamivudine 5 100.21 ± 2.05 102.47 ± 2.94 99.12 ± 1.71 t1 = 0.594 F1 = 2.060
t2 = 0.385 F2 = 1.440
Stavudine 1 95.00 ± 2.65 96 ± 2.94 97.65 ± 2.24 t1 = 0.238 F1 = 1.230
t2 = 0.720 F2 = 1.400
Lamivudine 10 102.4 ± 2.47 98.10 ± 2.5 100.92 ± 1.54 t1 = 1.153 F1 = 1.020
t2 = 0.479 F2 = 2571
Stavudine 2 97.00 ± 2.22 96.25 ± 2.17 97.80 ± 1.92 t1 = 0.228 F1 = 1.050
t2 = 0.257 F2 = 1.342
Lamivudine 15 98.50 ± 1.63 100.18 ± 0.92 100.44 ± 1.38 t1 = 0.661 F1 = 3.139
t2 = 0.702 F2 = 1.395
Stavudine 3 96.76 ± 1.27 98.17 ± 1.72 97.40 ± 1.55 t1 = 0.927 F1 = 1.834
t2 = 0.736 F2 = 1.489
Theoretical values for t- and F-tests at 95% conﬁdence limit are 2.31 and 6.39, respectively.
a Average of three determinations.
b F1, t1 for
1D/CLS methods and F2, t2 for
1D/PCR methods.
Table 3 Results obtained by applying CLS and PCR calibration methods to laboratory prepared mixtures of lamivudine and
stavudine in 0.1 M hydrochloric acid ± relative errors.
Compounds CLS PCR
Actual (lg ml1) Found (lg ml1) % ±Relative errors* Found (lg ml1) % ±Relative errors*
LAM 4.00 3.94 98.58 ± 1.53 3.95 98.80 ± 1.77
STA 10.00 9.88 98.77 ± 1.42 10.12 101.201 ± 1.79
LAM 6.00 5.98 99.72 ± 1.63 5.92 98.62 ± 1.65
STA 8.00 7.95 99.42 ± 1.55 8.07 100.91 ± 1.93
LAM 7.00 6.96 99.43 ± 1.50 7.09 101.31 ± 1.22
STA 7.00 6.89 98.43 ± 1.62 6.99 99.80 ± 1.58
LAM 8.00 8.05 100.62 ± 1.45 8.10 101.30 ± 1.34
STA 6.00 5.94 99.00 ± 1.10 6.02 100.03 ± 1.88
LAM 10.00 10.09 100.90 ± 1.14 10.11 101.13 ± 1.04
STA 4.00 3.87 98.75 ± 1.73 3.93 98.23 ± 1.97
LAM 10.00 10.13 101.30 ± 1.35 9.95 99.46 ± 1.08
STA 2.00 1.93 98.50 ± 2.00 1.97 98.35 ± 1.84
* Relative errors as calculated from the corresponding binary mixtures results (n= 3).
Table 2 Predicted concentrations of pure stavudine samples in 0.1 M hydrochloric acid ± relative errors as calculated from CLS and
PCR calibration methods.
Concentrations (lg ml1) CLS PCR
Found (lg ml1) % ±Relative errorsa Found (lg ml1) % ±Relative errorsa
3.00 2.89 98.33 ± 1.96 2.95 98.40 ± 1.96
4.00 3.83 98.33 ± 1.41 3.95 98.65 ± 1.88
5.00 4.96 99.10 ± 1.10 4.93 98.66 ± 1.86
6.00 5.91 97.94 ± 1.48 5.88 98.07 ± 1.23
7.00 6.91 98.76 ± 1.48 6.91 98.73 ± 1.67
8.00 7.99 99.88 ± 0.48 7.92 99.01 ± 1.33
9.00 9.04 100.44 ± 0.63 9.05 100.58 ± 1.74
10.00 10.19 101.91 ± 1.24 10.02 100.23 ± 2.05
11.00 11.09 101.82 ± 1.21 10.96 99.68 ± 0.98
12.00 12.08 100.70 ± 0.71 12.11 100.92 ± 0.92
a Relative errors as calculated from the corresponding calibration model (n= 3).
Determination of lamivudine and stavudine in pharmaceutical preparations 279
280 A.E.-M.I. Mohamed, W. Mikrethe mixtures containing low concentrations of stavudine (10:4
and 10:2 lamivudine:stavudine, respectively).
3.4. Analysis of commercial tablets
The proposed methods were used for the simultaneous deter-
mination of lamivudine and stavudine in pharmaceuticals
without prior separation of the excipients and additives present
in the commercial tablets. Table 4 shows the results obtained
form the analysis of Coviro-LS tablets that contain 150 mg
of lamivudine and 30 mg of stavudine at three concentration
levels. The results indicated that the proposed techniques could
be used for simultaneous quantitation and routine quality con-
trol analysis of this binary mixture in pharmaceuticals.
In order to provide the accuracy and precision of the pro-
posed procedures a comparison between the used methods
and 1D reported method (Kapoor et al., 2006) were done.
According to the t-test and F-test, all the calculated t-values
and F-values were smaller than the theoretical values at the
95% conﬁdence level. This indicates that there is no signiﬁcant
difference between the performances of the used techniques
and the reported method with regard to the mean values and
their variances (Table 4).
Regarding these results and the recovery studies done for
the pure compounds added to the commercial tablets which
indicate the absence of the interferences due to the presence
of the excipients and additives, we can conclude that the pro-
posed methods are sufﬁciently accurate and precise in order to
be applied to the pharmaceutical dosage forms.
4. Conclusion
The contents of several laboratory prepared mixtures and
commercial tablets were simultaneously determined using
UV-spectrophotometric measurements together with CLS
and PCR calibration analysis. The good recoveries obtained
in all cases as well as the reliable agreement with the reported
procedures proved that, the proposed procedures could be ap-
plied efﬁciently for determination of studied drugs simulta-
neously in their binary mixtures as well as in the commercial
dosage forms with satisfactory precision.
From the comparison of the results obtained with the pro-
posed methods and the 1D reported method, they do not ap-
pear to have substantial differences, but a little superiority of
the PCR technique over the 1D and CLS in the simultaneous
determination of lamivudine and stavudine was observed espe-
cially in the low concentrations of stavudine and in presence of
high background interferences.
The proposed procedures are rapid and sufﬁciently precise
and suitable for quality control laboratories, where the econ-
omy and time are important factors.
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